Lara Bull-Otterson1, Ya-Lin A Huang2, Weiming Zhu2, Hope King3, Brian R Edlin1, Karen W Hoover2. 1. Office of the Director, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA. 2. Division of HIV/AIDS Prevention, NCHHSTP, CDC, Atlanta, Georgia, USA. 3. Division of Viral Hepatitis, NCHHSTP, CDC, Atlanta, Georgia, USA.
Abstract
BACKGROUND: We assessed prevalence of testing for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection among persons who inject drugs (PWID). METHODS: Using a nationwide health insurance database for claims paid during 2010-2017, we identified PWID by using codes from the International Classification of Diseases, Current Procedural Terminology, and National Drug Codes directory. We then estimated the percentage of PWIDs tested for HIV or HCV within 1 year of an index encounter, and we used multivariate logistic regression models to assess demographic and clinical factors associated with testing. RESULTS: Of 844 242 PWIDs, 71 938 (8.5%) were tested for HIV and 65 188 (7.7%) were tested for HCV infections. Missed opportunities were independently associated with being male (odds ratios [ORs]: HIV, 0.50 [95% confidence interval {CI}, 0.49-0.50], P < .001; HCV, 0.66 [95% CI, 0.65-0.72], P < .001), rural residence (ORs: HIV, 0.67 [95% CI, 0.65-0.69], P < .001; HCV, 0.75 [95% CI, 0.73-0.77], P < .001), and receiving services for skin infections or endocarditis (adjusted ORs: HIV, 0.91 [95% CI, 0.87-0.95], P < .001; HCV, 0.90 [95% CI, 0.86-0.95], P < .001). CONCLUSIONS: Approximately 90% of presumed PWIDs missed opportunities for HIV or HCV testing, especially male rural residents with claims for skin infections or endocarditis, commonly associated with injection drug use. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: We assessed prevalence of testing for human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infection among persons who inject drugs (PWID). METHODS: Using a nationwide health insurance database for claims paid during 2010-2017, we identified PWID by using codes from the International Classification of Diseases, Current Procedural Terminology, and National Drug Codes directory. We then estimated the percentage of PWIDs tested for HIV or HCV within 1 year of an index encounter, and we used multivariate logistic regression models to assess demographic and clinical factors associated with testing. RESULTS: Of 844 242 PWIDs, 71 938 (8.5%) were tested for HIV and 65 188 (7.7%) were tested for HCV infections. Missed opportunities were independently associated with being male (odds ratios [ORs]: HIV, 0.50 [95% confidence interval {CI}, 0.49-0.50], P < .001; HCV, 0.66 [95% CI, 0.65-0.72], P < .001), rural residence (ORs: HIV, 0.67 [95% CI, 0.65-0.69], P < .001; HCV, 0.75 [95% CI, 0.73-0.77], P < .001), and receiving services for skin infections or endocarditis (adjusted ORs: HIV, 0.91 [95% CI, 0.87-0.95], P < .001; HCV, 0.90 [95% CI, 0.86-0.95], P < .001). CONCLUSIONS: Approximately 90% of presumed PWIDs missed opportunities for HIV or HCV testing, especially male rural residents with claims for skin infections or endocarditis, commonly associated with injection drug use. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Entities:
Keywords:
HIV seropositivity; drug users; hepatitis C; insurance coverage/statistics and numerical data; substance-related disorders
Authors: Raagini Jawa; Michael D Stein; Bradley Anderson; Jane M Liebschutz; Catherine Stewart; Kristina T Phillips; Joshua A Barocas Journal: AIDS Behav Date: 2021-09-12
Authors: Xinyi Jiang; Robert L Parker; Scott Martin Vouri; Weihsuan Lo-Ciganic; Vakaramoko Diaby; Linda Henry; Haesuk Park Journal: Am J Prev Med Date: 2021-06-29 Impact factor: 6.604
Authors: Tyler S Bartholomew; Hansel E Tookes; David P Serota; Czarina N Behrends; David W Forrest; Daniel J Feaster Journal: Int J Drug Policy Date: 2020-07-27